Position in AXSM
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$3,597,874
+$2,514,190 QoQ
Shares Held
14,699
+14.8% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#186
of 494 holders
Holding Since
Jun 2020
4 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in AXSM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Calamos Advisors LLC holds $119,502,354 across 21 Biotechnology names. AXSM ranks #8 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
75,388 | $37,447,481 | |
| 2 | RPRX |
Royalty Pharma plc
|
573,521 | $32,157,322 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
11,578 | $7,219,346 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
22,435 | $7,091,478 | |
| 5 | TVTX |
Travere Therapeutics, Inc.
|
121,755 | $6,916,901 | |
| 6 | CYTK |
Cytokinetics Inc
|
51,443 | $4,382,428 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
19,711 | $3,691,476 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
This page
|
14,699 | $3,597,874 |
All Filings in AXSM
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,597,874 | 14,699 | Shares | Sole | 2026-07-31 | |
| 2024-12-31 | $1,083,684 | 12,808 | Shares | Sole | 2025-01-24 | |
| 2023-06-30 | $916,573 | 12,755 | Shares | Other | 2023-07-28 | |
| 2020-06-30 | $694,935 | 8,446 | Shares | Other | 2020-07-27 | |
| No filing history on record for this holder in this stock. | ||||||